Cognition Therapeutics, Inc.
corporate_fare Company Profile
Cognition Therapeutics, Inc. (NASDAQ:CGTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CGTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for CGTX spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Cognition Q3 Loss Narrows to $4.1M; Cash Runs Into Q4 2027 as Nasdaq Deficiency Looms
- Cognition Therapeutics Receives Nasdaq Minimum-Bid Deficiency Notice, Has Until May 3, 2027 to Cure
- Cognition Confirms FDA Alignment on Phase 3 Zervimesine Trial in DLB
- FDA Signs Off on Pivotal Phase 3 Design for Cognition's DLB Drug
- Cognition Therapeutics Secures Composition of Matter Patent for Zervimesine Through 2045
Financial Snapshot
Short Interest & Short Volume
15.27 days to coverFINRA reported short interest of 6,916,762 shares in CGTX as of the October 30, 2026 settlement, a 1.7% decrease from the prior period — about 15.3 days to cover at its recent average daily volume. On November 20, 2026, 53.0% of CGTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.